Levera 750 Tablet contains Levetiracetam 750 mg, an antiepileptic medication primarily indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, which is believed to inhibit abnormal neuronal firing and reduce seizure activity. This medication is typically prescribed as adjunctive therapy in adults and pediatric patients aged four years and above. Levera 750 Tablet is well-absorbed orally, with rapid onset of action and minimal hepatic metabolism, thereby reducing the risk of drug interactions. Common adverse effects may include somnolence, dizziness, fatigue, and behavioral symptoms such as irritability or mood changes; however, it is generally well-tolerated. Dosage should be individualized based on clinical response and renal function, with gradual titration recommended to minimize side effects. Patients should be advised not to discontinue therapy abruptly to prevent seizure recurrence. Regular monitoring and consultation with a healthcare professional are essential to optimize therapeutic outcomes and manage potential adverse reactions. Levera 750 Tablet should be used under strict medical supervision, especially in patients with a history of psychiatric disorders or renal impairment.